Baillie Gifford & Co’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-219,400
| Closed | -$730K | – | 233 |
|
|
2019
Q4 | $730K | Hold |
219,400
| – | – | ﹤0.01% | 209 |
|
|
2019
Q3 | $667K | Hold |
219,400
| – | – | ﹤0.01% | 211 |
|
|
2019
Q2 | $523K | Hold |
219,400
| – | – | ﹤0.01% | 219 |
|
|
2019
Q1 | $823K | Hold |
219,400
| – | – | ﹤0.01% | 217 |
|
|
2018
Q4 | $787K | Hold |
219,400
| – | – | ﹤0.01% | 216 |
|
|
2018
Q3 | $1.26M | Hold |
219,400
| – | – | ﹤0.01% | 211 |
|
|
2018
Q2 | $1.1M | Hold |
219,400
| – | – | ﹤0.01% | 204 |
|
|
2018
Q1 | $1.13M | Hold |
219,400
| – | – | ﹤0.01% | 202 |
|
|
2017
Q4 | $1.32M | Hold |
219,400
| – | – | ﹤0.01% | 196 |
|
|
2017
Q3 | $1.22M | Hold |
219,400
| – | – | ﹤0.01% | 194 |
|
|
2017
Q2 | $1.02M | Hold |
219,400
| – | – | ﹤0.01% | 196 |
|
|
2017
Q1 | $1.09M | Hold |
219,400
| – | – | ﹤0.01% | 195 |
|
|
2016
Q4 | $2.44M | Hold |
219,400
| – | – | ﹤0.01% | 190 |
|
|
2016
Q3 | $2.03M | Hold |
219,400
| – | – | ﹤0.01% | 192 |
|
|
2016
Q2 | $1.39M | Hold |
219,400
| – | – | ﹤0.01% | 191 |
|
|
2016
Q1 | $1.43M | Hold |
219,400
| – | – | ﹤0.01% | 191 |
|
|
2015
Q4 | $1.78M | Hold |
219,400
| – | – | ﹤0.01% | 176 |
|
|
2015
Q3 | $1.61M | Buy |
219,400
+30,000
| +16% | +$306K | ﹤0.01% | 185 |
|
|
2015
Q2 | $1.94M | Buy |
+189,400
| New | +$2.09M | ﹤0.01% | 182 |
|
Baillie Gifford & Co's FOMX Position: Q1 2020 in Review
Baillie Gifford & Co sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 219,400 shares — an estimated $730K sold.
Baillie Gifford & Co first reported a position in FOMX in Q2 2015 and held it in 19 quarters. The position peaked at $2.44M in Q4 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Baillie Gifford & Co reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Baillie Gifford & Co sold 219,400 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $730K.
- Baillie Gifford & Co first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 19 quarters.
- Baillie Gifford & Co's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $2.44M in Q4 2016.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Baillie Gifford & Co's 13F filing for Q1 2020, filed 8 May 2020.